Navigation Links
Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
Date:12/9/2010

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

Paclitaxel/carboplatin are commonly used chemotherapy drugs in lung cancer patients. Ipilimumab is a human monoclonal antibody that is used to activate the immune system. It works by blinding to and blocking the activity of CTLA-4, a molecule on T-cells that is thought to play a large role in regulating natural immune responses, which as a result sustains an active immune response when attacking cancer cells.

Researchers in this randomized phase II trial sought to determine if adding ipilimumab to treatments for stage IIIb/IV lung cancer patients would impact overall survival and progression free survival. Over 200 patients were treated using ipilimumab plus a concurrent schedule of paclitaxel/carboplatin, ipilimumab plus a phased schedule of paclitaxel/carboplatin or paclitaxel/carboplatin alone.

With both schedules, using ipilimumab in combination with paclitaxel/carboplatin showed improved progression free survival rates when compared to paclitaxel/carboplatin alone. The phased schedule did show better efficacy than the concurrent schedule, but in no instance did ipilimumab increase paclitaxel/carboplatin related toxicity.

"Phase III and IV lung cancers do not often see positive end results, so there is a lot of room to improve treatments for this disease," Thomas Lynch, M.D., lead author of the study, a professor of medicine at Yale University in New Haven, Conn., and director of the Yale Cancer Center, said. "Ipilimumab is one of the few immunotherapies that have shown positive results in treating lung cancers, and if adding this to standard treatments can improve survival, then it is worth further trials."


'/>"/>

Contact: Beth Bukata
bethb@astro.org
703-431-2332
American Society for Radiation Oncology
Source:Eurekalert

Related medicine news :

1. Alzheimers Association Applauds Social Security Administration for Adding Early-Onset Alzheimers to Its Compassionate Allowances Initiative
2. Adding Surgery to Meds May Improve Life With Parkinsons
3. Ellsworth Adhesives Is Adding PRC Rapid Seal Product Line Offering
4. Adding Recess to the Workday Gains Backers
5. Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival
6. Adding radiation to hormone therapy for prostate cancer treatment will increase survival chances
7. Adding Monounsaturated Fats to Diet May Boost Heart Health
8. Adding monounsaturated fats to a low-cholesterol diet can further improve levels
9. Adding pharmacists to docs offices helps patient outcomes, study shows
10. Adding Surgery to Meds May Help Diabetics With Heart Disease
11. One-third of antimalarial medicines sampled in 3 African nations found to be substandard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... ... A new partnership between Goodwill® and Roadie, Inc. aims to make it ... to couches to dressers and bicycles. Roadie — the national on-the-way delivery network — ... center through February 28th. , “January is an exciting time when resolutions are ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Bionic Sports Nutrition ... walks of life, announced it had a successful January ECRM Trade Show in Hilton ... the United States, which allows it to provide its products to all clients at ...
(Date:1/20/2017)... raton florida (PRWEB) , ... January 20, 2017 , ... ... at the Dana Farber Cancer Institute. For Betsy, the clinical trial has been ... her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian cancer ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “The Angel”: ... the Lord has set out for each of his children. “The Angel” is the ... School of Music in New York City, and impassioned writer. , When asked of ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a ... author, Sara Seymour, who lives in Lafayette, Indiana where she works in a daycare ... coffees and writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Today, ... Symposia Conference, "PI3K Pathways in Immunology, Growth ... (NASDAQ: INFI ) presented ... development candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). ... to help overcome resistance to checkpoint inhibition ...
(Date:1/20/2017)... CINCINNATI , Jan. 20, 2017 /PRNewswire/ ... has acquired Megadyne Medical Products, Inc., a ... manufactures and markets electrosurgical tools used in ... the intelligence of Ethicon,s* advanced energy devices ... representing a major step forward in Ethicon,s ...
(Date:1/20/2017)... January 20, 2017 ... an Nothilfe   Die internationale humanitäre Stadt soll ... zu schaffen   Seine Hoheit Scheich ... VAE sowie Herrscher von Dubai , ... der Hilfe (International Humanitarian City IHC) zu verdreifachen, um ...
Breaking Medicine Technology: